GTC Biotherapeutics (fka GTCB)

[keitern]

From RMF:

"4. An ATryn partnership in Japan. Japan has substantial sales of plasma-derived antithrombin, including an approved indication for DIC/sepsis. These plasma-derived sales represent low-hanging fruit for eventual conversion to ATryn. At least one Japanese clinical study will be needed to obtain marketing approval. Dr. Cox has said that a deal is more likely in 2009 than in 2008."

Re. P.D. antithrombin in Japan, how can this be approved unless some validation has occurred? And if validation at some meaningful level, should this make us feel more comfortable with eventual FDA trials? Thanks.